v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
SCHEDULE OF DISAGGREGATED REVENUE

The Company’s disaggregated revenue by category is as follows:

   June 30, 2026   June 30, 2025 
   For the three-months ending, 
   June 30, 2026   June 30, 2025 
Sale of pharmaceutical products, shipping income and medical consultations  $8,994,351   $8,749,421 
Other   31,428    10,769 
Total Revenue, net  $9,025,779   $8,760,190 
SCHEDULE OF ACCOUNTS RECEIVABLE

   As of 
   June 30, 2026   March 31, 2026 
Accounts receivable, net  $845,945   $356,054